Carfilzomib for treating myeloma - sprookjes - yvandenbroek - TriplyDB

Carfilzomib for treating myeloma

Carfilzomib for treating myeloma

http://www.wikidata.org/entity/Q57904173

about

An overview of the role of carfilzomib in the treatment of multiple myeloma.

P2860

Q50035012-8FFD0EB6-E2EF-4593-851E-BE66830BD358

P2860

Carfilzomib for treating myeloma

http://www.wikidata.org/entity/Q57904173

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2016

@uk

name

Carfilzomib for treating myeloma

@en

Carfilzomib for treating myeloma

@nl

type

label

Carfilzomib for treating myeloma

@en

Carfilzomib for treating myeloma

@nl

prefLabel

Carfilzomib for treating myeloma

@en

Carfilzomib for treating myeloma

@nl

P1433

Q57904173-30C118E5-5784-4B66-9B8A-E185938ACAF4

P1476

Q57904173-4B6CA3B2-9AB9-4EF7-873B-BB77B1683B4B

P2093

Q57904173-24A89466-0361-453B-AAC4-ACB477AC2A60

Q57904173-BD7F4DCE-EED4-4894-A6AB-E09B36521A80

P2860

Q57904173-003FE529-EDBB-40E5-BA19-5024B807449E

Q57904173-065A3A8D-17F7-4144-9DD3-997045236B40

Q57904173-0CDB2D24-4AB7-4005-8FDD-EA021A3F545B

Q57904173-1065F500-44CB-40FD-89C4-FEF2D7979D16

Q57904173-12CDF645-E003-469A-A818-E7513EC86912

Q57904173-1D4F12C3-06C7-4F46-9071-C7F3DCD3830A

Q57904173-1E857273-A572-497F-A998-2A67F9B9675C

Q57904173-1FC8B401-D90D-4A07-BEC5-D6787FB348FD

Q57904173-20ECDA1D-3A1D-4E91-942A-0DD867EDBF62

Q57904173-2217CC50-FF94-440E-B02F-6A386F186138

P304

Q57904173-C9824576-17DD-48BD-84A9-6B854C260077

P31

Q57904173-2CD55BDC-4930-4E9E-A878-E5AEE43A0759

P356

Q57904173-FCC7FCB7-A37F-4748-B611-A824521CF87E

P433

Q57904173-8CC132D4-22DB-44B2-B645-8DA7E3C9E913

P478

Q57904173-941241C4-04B5-4D82-AFF8-3837586D3432

P50

Q57904173-AB32C689-A7CE-4B0E-A91B-C222CCEF63EC

Q57904173-C5E7E944-91E5-4EFA-B2A9-B8394826B894

P577

Q57904173-5F428490-19E2-4153-9D23-13A734671CED

P356

21678707.2016.1215909

P1433

Expert opinion on orphan drugs

P1476

Carfilzomib for treating myeloma

@en

P2093

Dimitrios C. Ziogas

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

P2860

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

The ubiquitin-proteasome proteolytic pathway

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

P304

989-999

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21678707.2016.1215909

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2016-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime